Related Experiment Video
Updated: Apr 21, 2026

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
Published on: March 12, 2019
Dynamic changes in the hypothalamic-pituitary-adrenal axis during growth hormone therapy in children with growth
Insights
Recombinant human growth hormone (rhGH) therapy reduced cortisol levels, especially in children with multiple pituitary hormone deficiencies (MPHD). Monitoring the hypothalamic-pituitary-adrenal (HPA) axis is crucial during rhGH treatment.
Area of Science:
- Pediatric Endocrinology
- Endocrinology
- Hormone Therapy
Background:
- Growth hormone deficiency (GHD) affects children's growth and development.
- The hypothalamic-pituitary-adrenal (HPA) axis regulates stress response and metabolism.
- Recombinant human growth hormone (rhGH) therapy is a standard treatment for GHD.
Purpose of the Study:
- To investigate the impact of rhGH therapy on the HPA axis in children with GHD.
- To assess changes in cortisol levels during rhGH treatment.
- To compare HPA axis response in children with isolated GHD versus multiple pituitary hormone deficiencies.
Main Methods:
- A multicenter, retrospective study of 72 children with GHD treated with rhGH for 6 months.
- Patients were categorized into isolated GHD (IGHD) and multiple pituitary hormone deficiencies (MPHD) groups.
- HPA axis and hormone levels were evaluated at baseline and every 3 months.
Main Results:
- Cortisol levels significantly decreased in MPHD patients receiving rhGH therapy.
- A subset of MPHD patients (10/52) exhibited low cortisol levels post-therapy.
- Cortisol levels also decreased in the IGHD group but remained within the normal range.
Conclusions:
- rhGH therapy is associated with reduced cortisol levels, particularly in children with MPHD.
- Close monitoring of the HPA axis is recommended during rhGH therapy.
- Further research may explore the long-term implications of these HPA axis changes.
Objective:
The objective of this study was to investigate changes in the hypothalamic-pituitary-adrenal (HPA) axis after recombinant human growth hormone (rhGH) therapy.
Subjects:
Subjects included children with growth hormone deficiency (GHD).
Methods:
We conducted a multicenter, retrospective study that assessed 72 GHD patients treated with rhGH during 6 months. Patients were classified into two groups: isolated GHD (IGHD; n=20) and multiple pituitary hormone deficiencies (MPHD; n=52). The HPA axis and other hormones were evaluated at baseline and every 3 months.
Results:
In the MPHD group, 32 patients had adrenocorticotrophic hormone deficiency and received hydrocortisone before rhGH therapy. In the other 20/52 MPHD patients, the cortisol (COR) level was significantly reduced after rhGH therapy. Moreover, 10 patients showed low COR levels. In the IGHD group, COR levels also decreased, but remained within the normal range.
Conclusion:
During rhGH therapy, COR levels were reduced, particularly in patients with MPHD. HPA axis should be monitored during rhGH therapy.
Related Concept Videos
Hypothalamic-Pituitary Axis
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome II: Pathophysiology
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
Nature and Nurture
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...

